Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC

Imamura, F; Inoue, T; Kunimasa, K; Kubota, A; Kuhara, H; Tamiya, M; Nishino, K; Kimura, M; Kuno, K; Kawachi, H; Kumagai, T

LUNG CANCER MANAGEMENT, 2020; 9 (2):

Abstract

Aim: We evaluated the efficacy of a novel switch protocol for EGFR-TKIs for EGFR mutation-positive NSCLC. Materials & methods: Clinical records we......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索